Nivolumab exposure in a hemodialysis patient with metastatic melanoma

Judith L Gulikers, Sander Croes, Marco J W Schreurs, Elisabeth J R Litjens, Maureen J B Aarts, Robin M J M van Geel*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


The effect of intermittent hemodialysis (IHD) on nivolumab serum concentrations in patients with severe renal impairment is largely unknown. Here, we present a 79-year-old patient with metastatic melanoma and end-stage renal disease on IHD three times a week, treated with 480 mg nivolumab every 4 weeks. A serum trough concentration of nivolumab was determined before the start of the third cycle, and two samples were taken immediately before and after a hemodialysis session during this cycle. All nivolumab serum concentrations were within a similar range as those previously measured among patients without renal insufficiency, after a comparable duration of nivolumab treatment. Therefore, we conclude that IHD does not influence nivolumab exposure. Furthermore, nivolumab treatment was continued without complications and appears to be well tolerated for patients on IHD.

Original languageEnglish
Pages (from-to)579-581
Number of pages3
JournalMelanoma Research
Issue number6
Publication statusPublished - 1 Dec 2021


  • hemodialysis
  • nivolumab
  • metastatic melanoma


Dive into the research topics of 'Nivolumab exposure in a hemodialysis patient with metastatic melanoma'. Together they form a unique fingerprint.

Cite this